Here are the 10-K annual reports from STRATA Skin Sciences Inc (SSKN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SSKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SSKN filings page.
STRATA Skin Sciences develops and markets medical devices for dermatology, led by its XTRAC excimer laser and VTRAC lamp systems for psoriasis, vitiligo and other inflammatory skin diseases, and the TheraClear X acne system. XTRAC in the U.S. is mainly placed under a recurring per-use revenue model with 842 partner clinics as of December 31, 2025.
The company reported a net loss of about $6.3 million for 2025 and an accumulated deficit of about $254.4 million. A Nasdaq delisting in February 2026 triggered an event of default under its MidCap term loan, causing all long‑term debt to be classified as current and creating substantial doubt about its ability to continue as a going concern.
Reimbursement is central to the model: Medicare national CPT rates for XTRAC treatments in 2025 ranged from $137 to $183 per treatment, and revised excimer CPT descriptors effective January 1, 2027 are expected to expand covered indications to additional autoimmune skin conditions. STRATA also faces sales‑tax disputes totaling several million dollars and supply‑chain risks tied to rare gases used in its lasers.